INTRODUCTION
An ear lacking a critical neurotransmitter pathway responds to gene therapy and consequently to sound. 1 An ear traumatized by excessive noise regains function. 2 These two recent studies demonstrate the use of genetic manipulations to restore hearing in ears with sensorineural hearing loss, one due to an inherited mutation and the other due to overstimulation. These and other studies are challenging the textbook characterization of sensorineural hearing loss being permanent. Although significant hurdles remain, recent research progress has brought us closer to making the dream of a more complete recovery from sensorineural hearing loss a clinical reality.
Lifespan in developed countries has expanded significantly in recent decades. As we age, tissues and cell types that are not spontaneously replaced often exhibit the first manifestations of a functional decline that reduces the quality of life. Several components of the inner ear, especially the sensory hair cells, the associated auditory and vestibular neurons and the stria vascularis, are among the tissues most affected by the aging process, leading to sensorineural hearing loss and balance disorders (see Figure 1 for a schematic representation of the target cells). Similar functional deficits also often manifest earlier in life due to acute damage from environmental trauma (side effects of medication, sound overstimulation or pathogenic infections), hereditary diseases (congenital or progressive) and combinations of these factors. Two to three out of every 1000 children in the United States are born with significant deafness, and over 35 million adults report some degree of hearing loss (http://www.nidcd.nih.gov/health/statistics/Pages/quick.aspx). In addition, 25 million Americans experience tinnitus, or ringing in the ears, a condition that often accompanies hearing loss. These sensory pathologies can lead to debilitating social isolation, depression, decreased economic opportunities and lower quality of life. Owing to the prevalence of this most common sensory deficit, the impact of treatments to preserve the ear and to more fully restore hearing would be immense.
Current clinical solutions to ameliorate hearing loss include amplification (hearing aids) when the deficit is mild to moderate, and cochlear implants (CIs) when the deficit is severe to profound. Although the CI is arguably the most successful neural prosthesis in clinical use, 3 the results are not always optimal and room for improvement has been reported by most users, especially in challenging listening environments. Recent progress in gene therapy demonstrates biological procedures that could improve hearing in combination with the CI or independently. These exciting and promising recent accomplishments are of potential applicability for both hereditary and environmentally caused inner ear diseases. This review describes the opportunities for novel gene therapy approaches and lists several recent breakthroughs accomplished in living animals, demonstrating future alternatives to hearing aids and CIs, and potential combination therapies for hearing restoration.
GENETIC DEAFNESS
Therapies to correct hearing loss with a genetic etiology must begin with knowledge of the causative genes. Traditional linkage and positional cloning strategies, and more recently, highthroughput genomic sequencing approaches, have identified mutations in over 60 different genes that lead to nonsyndromic hearing loss in humans (Hereditary Hearing Loss Homepage: http://hereditaryhearingloss.org/). Mutations in a similarly large number of genes also underlie syndromic disorders that include hearing loss as part of the affected phenotype. The proteins encoded by the majority of these genes exhibit a wide range of known or predicted functions, including ion channels, cell surface proteins and transcription factors. 4, 5 These mutations are most often transmitted in a recessive manner, produce loss of gene function and are associated with congenital or early-onset hearing loss. A second class of mutations is transmitted in a dominant manner, typically resulting in gain of gene function and lateronset progressive hearing loss. In addition, mutations in genes encoding mitochondrial RNAs 6 and a micro RNA 7 have also been implicated in hearing-loss disorders.
The therapy for genetic hearing loss ideally requires identification of the specific cells in which each mutation exerts its effect. Analyses of mouse models carrying mutations in genes associated with human hearing loss have been instrumental in understanding the role these genes have in the development and maintenance of auditory function. These studies have demonstrated a wide variety of primary affected cell types in the inner ear, often sensory hair cells and/or auditory nerve cells, but also epithelial supporting cells, mesenchymally derived cells, cells of the stria vascularis and even extracellular domains such as the tectorial membrane. 4 Recent success in delivery of the normal version of a mutant gene in a mouse genetic model of recessively inherited, earlyonset hearing loss has elegantly demonstrated the feasibility of gene therapy approaches to correct sensory function. 1 Mice carrying homozygous mutations in Vglut3 are profoundly deaf due to the loss of transport of a key neurotransmitter (glutamate) required for synaptic transmission at the inner hair cell-auditory nerve synapse. 8, 9 Akil et al. 1 demonstrated that delivery of wild-type Vglut3 using an adeno-associated virus to the inner ears of the mutant mice within the first 10 days after birth resulted in a nearly complete and sustained recovery of hearing sensitivity. 1 The authors noted, however, that despite this dramatic rescue, the numbers of auditory nerve cells in the treated mutants were still less than those in the normal-hearing mice and suggested that the mice likely did not recover complete sensory function. To be clinically applicable, it will be necessary to show that this technology also works in mature ears, as treating developing human ears is impractical because the human ear completes development in utero. In addition, many mouse genetic models as well as human temporal bone studies demonstrate that degeneration of affected cells often occurs after onset of the functional deficit. Nevertheless, this study highlights the potential as well as the challenges of gene therapy in the inner ear.
Treatment of later-onset progressive hearing loss offers potential advantages relative to congenital hearing loss in that initially all cell types in the cochlea are present and functioning normally. Although the functional nature of many of the dominant mutations most often associated with progressive hearing loss has not been studied in detail, many appear to act as gain-of-function mutations. In such cases, potentially targeted genetic therapies would require selective inhibition of the mutant allele. The feasibility of this approach has been preliminarily demonstrated in a mouse model expressing a gain-of-function, dominant-negative isoform of Gjb2, which encodes a critical gap junction connexin protein in the cochlea. Hearing loss associated with the mutant allele was diminished by inner ear delivery of duplex small interfering RNA (siRNA) directed at the mutant Gjb2 transcript. 10 This protective effect of the siRNA correlated with selective reduction in expression of the mutant allele relative to expression of the endogenous wild-type allele. Similar interventions at the RNA level could be used to reduce the effects of mutations that cause aberrant overexpression, as in the case of a 5 0 -untranslated region mutation in the DIAPH3 gene in individuals with one form of auditory neuropathy. 11, 12 In some cases, supplementation of genes acting downstream of a mutated gene may also provide therapy.
ACQUIRED (ENVIRONMENTAL) DEAFNESS Protection
Many people are exposed to potentially damaging loud sounds and noises in their workplaces, from the farm and the factory floor to the restaurant kitchen. A soldier on a routine mission is exposed to machine gun fire and other potentially ear-damaging acoustic inputs. A cancer patient often receives a common antitumor agent such as cisplatinum, which is also ototoxic. Similarly, airway infections in cystic fibrosis patients are often treated with ototoxic aminoglycoside antibiotics. Common to all these situations is the high likelihood for hearing loss, which may start as a mild deficit and progress to a very debilitating deficiency. Approaches aimed at reducing or preventing the lesions in the inner ear and the associated hearing loss are effective in some cases, such as conventional earplugs in the case of overstimulation. In other cases, however, protective equipment is often inadequate, impractical or simply unavailable. Gene therapy approaches offer promise as alternatives to provide protection from environmental traumas.
Animal model experiments have shown inner ear protection using several genes from different gene families. For instance, overexpression of the antioxidant gene catalase via adenovirus gene transfer resulted in increased levels of catalase in the cochlear fluids of the guinea pig ear and in protection against ototoxicity. 13 Gene therapy was also shown to protect both hair cells and auditory neurons. [14] [15] [16] [17] Similarly, overexpression of antiapoptotic genes has been used to prevent the loss of hair cells. 57,58 GJB2 is expressed in SCs, fibrocytes of the lateral wall and epithelial cells at the medial side of the cochlea (in gray), and in a subset of cells of the SV.
59-61 VGLUT3 (also known as SLC17A8), which encodes a vesicular glutamate transporter, is expressed in IHCs. 9 Cochlear delivery of a wild-type version of VGLUT3 rescued auditory function in mice homozygous for mutations in this gene (see text for details).
1 Injection into the fluid-filled spaces of the cochlea of adenoviral or adeno-associated viral vectors encoding BDNF resulted in expression of the neurotrophin in SCs and in mesothelial cells (MC; in dark blue) that line the scala tympani space and induced the regrowth of auditory nerve fibers. 37, 62 For instance, in inner ears exposed to the ototoxic aminoglycoside antibiotic neomycin, pretreatment with an adenovirus carrying the Bcl-2 gene insert protected hair cells and preserved hearing in mice. 18 Furthermore, a trans-tympanic delivery of siRNA against STAT1 attenuated cisplatin ototoxicity. 19 The animal studies mentioned above used a surgical approach for delivering the protective viral vector or siRNA into the cochlea. The need for surgery limits the applicability for practical clinical use because there are risks involved in the surgery that clearly outweigh the potential protection. These animal studies, therefore, provided proof of principle for the protective potential of inner ear gene therapy and paved the way for pursuing the next step: how can such protective outcomes be accomplished without the need and risk of surgery. Methods for delivering viral vectors or small molecules using a trans-tympanic approach are being pursued. Using these approaches, delivery of dexamethasone, 20 antagonizing reactive oxygen species 19 or inducing a pharmaceutical elevation in the levels of heat shock proteins 21 showed promise for a protective outcome. Ideally, protective therapy should be delivered via ear drops or systemic medication, which could be administered under any conditions by the end user. Our ability to prevent the loss of hair cells should also benefit from better understanding of the molecular signaling involved in the process of cochlear hair cell death. Degenerating hair cells undergo phagocytosis by the neighboring supporting cells. 22 The latter form scars that preserve the reticular lamina.
23,24
Once we better understand the signaling mechanisms leading to phagocytosis and scarring, it may be possible to use gene therapy to modulate signaling and prevent the loss of hair cells.
Repair and regeneration
Once the cells are damaged or lost, a reparative/regenerative therapy is needed for restoring hearing. Replacing lost cells (such as hair cells) or restoring function in a cellular compartment that is damaged, such as the synaptic region between the inner hair cell and the auditory neuron, are the typical examples of therapeutic targets. Several therapies are also being proposed in combination with the CI prosthesis to improve the benefits that patients derive from their prostheses. Regeneration of hair cells is a much-needed clinical option because loss of hair cells is among the more common causes for deafness. When the cause of hair cell loss is not genetic, there is a good likelihood that placing regenerated hair cells in the cochlea may restore hearing. Mouse genetic studies have also provided insight into genes that are relevant to replacement of cells, including hair cells and auditory neurons that have been lost due to the primary or secondary effects of environmental trauma or inherited mutations. Analysis of loss of function mutations in Atoh1, which encodes a basic helix-loop-helix transcription factor, demonstrates the necessity of this gene to drive the normal post-mitotic differentiation of sensory hair cells during development. 25 Several groups have delivered this gene to nonsensory cells in the mature damaged cochlea and induced the formation of small numbers of new, ectopic hair cells, 26, 27 indicating that it is sufficient to regenerate sensory cell fate from a subset of remaining cell types. However, in ears where the auditory epithelium has been reduced to a flat undifferentiated epithelium, an end point in degeneration of the auditory epithelium, ectopic expression of Atoh1 failed to induce regeneration. 28 This fact, along with technical difficulties in delivering the viral vectors to the cochlear fluid compartment where they are needed, and with the potential for side effects from the vector itself, makes this approach clinically irrelevant at the present time.
The final numbers and highly organized mosaic of sensory cells in the mature cochlea also depend upon a complex interplay of additional genes encoding transcription factors and cell signaling pathway proteins, including members of the Notch pathway. 29 Modulation of the Notch pathway, presumably by affecting its activity in lateral inhibition of sensory cell fates, can also alter the final numbers and arrangement of the sensory epithelium in the cochlea. 29 Recently, inhibition of gamma secretase, which is required for normal Notch activation, in the inner ears of mice 1 day after exposure to a loud noise was found to induce transdifferentiation of nonsensory supporting cells into new outer hair cells and provide a significant increase in hearing sensitivity relative to untreated controls. 2 Use of markers that are supporting cell-specific helped identify the new hair cells as they derived from previously differentiated supporting cells. The finding enhances the feasibility for clinical use of hair cell regeneration, especially because the route used to introduce the vector was compatible with that used in the human ear, and the reagent has limited or no side effects when used locally. Once this treatment is optimized to efficiently produce new hair cells when given weeks or months after a lesion, its clinical relevance will significantly increase. This study, along with other work showing transdifferentiation induced with gamma secretase inhibition, 30 are encouraging for the eventual realization of clinical hair cell regeneration.
Gene therapy for blocking cell cycle inhibition (enhancing mitosis) showed a mild induction of proliferation in nonsensory cells but did not, by itself, lead to the generation of new hair cells. 31 However, several studies have shown that transgenic mice in which cell cycle inhibition is removed in the auditory sensory epithelium exhibit continued proliferation and presence of supernumerary hair cells. [32] [33] [34] [35] Induced proliferation should be explored in parallel to inducing transdifferentiation of supporting cells because replenishing the number of nonsensory cells may be crucial for hearing.
The extent of hearing restoration does not need to be complete to afford clinical benefits. However, attempts to generate new hair cells need to consider possible undesirable side effects that may derive from factors such as mis-location, mis-orientation or incorrect innervation of these cells, both at the periphery and in the brain. Side effects may include tinnitus, distorted sound perception or abnormal thresholds. It is hoped that brain plasticity and compensation will help accommodate the new signals that will be relayed by the auditory nerve.
CIs are the only current therapeutic options for ears with hereditary deafness in which hair cells are missing or dysfunctional but auditory nerve is present. In some cases, the neurons also degenerate following hair cell loss. In such cases, the benefits from the CI decrease. A recent study showed that gene therapy with Ad.BDNF enhanced the preservation of auditory neurons in a mouse model for human deafness. 36 The neurons in these treated ears exhibited pronounced sprouting into the auditory epithelium, despite the absence of hair cells. Similar ability to preserve auditory nerve cells and induce their sprouting has also been demonstrated in a guinea pig model for induced ototoxic ear lesions by the use of neurotrophin gene therapy. 16, 37 These two examples involve the auditory nerve as a target for therapy and show how gene transfer approaches can change the inner ear with the goal of enhancing the biological substrate for CI therapy. Other combinatorial therapies could also be possible. For instance, combining CI therapy with regenerating new hair cells in the cochlear apex should likely enhance the combined outcome, as it may improve nerve survival and function and provide low-frequency acoustic hearing. Combining hair cell regeneration in the sensory area of the auditory epithelium with measures to augment function of the stria vascularis may enhance function in many cases of agerelated hearing loss where the age-related lesion may include both regions of the cochlea. 38, 39 Other cellular targets that can be manipulated for preventive or regenerative purposes include the stria vascularis and possibly the population of Schwann cells that myelinate the auditory nerve.
ROUTES FOR DELIVERING GENE THERAPY REAGENTS FOR DEAFNESS THERAPY
The delivery of reagents for gene therapy in the inner ear needs to be reliable, safe and consistent to accomplish the goals. Delivering genes with viral vectors is potentially the most efficient method. Most experiments have used adenoviral or adeno-associated viral vectors. [40] [41] [42] [43] However, other options exist. [44] [45] [46] [47] Selection of the optimal vector should consider potential side effects, cell specificity, duration of gene expression and access for delivery. Several parameters that are acceptable and practical for animal experimentation are less acceptable or impractical for use in the clinic. The main limitations are the potential immune response, lack of access to the scala media, variability in the outcome and the lack of specificity to the type of cell transduced. Improved vectors will likely resolve at least some of these limitations if they can reach the target cell via a surgically feasible route (perilymph), drive transgene expression in a cell-and temporally-specific manner, and have no side effects.
Delivery of siRNA is less specific than that of viruses, but the likelihood for side effects is also reduced and the ability to deliver the reagent without violating the cochlear space is a significant advantage, as seen in several studies. 19, 48, 49 When short-term activity of the delivered reagent is sufficient for the desired biological effects, use of a small molecule to influence gene expression in the inner ear is an attractive option. 2, 30 Nanoparticles have also been used for inner ear delivery, including delivery to the perilymph through the round window membrane, which is a clinically feasible procedure. [50] [51] [52] Although the outcome is usually less efficient and less specific than viral vector-mediated gene transfer, the potential for gene delivery without drilling into the cochlea makes nanoparticles an attractive option for protecting the ear or repairing it.
Combination of more than one delivery route may also be applicable in specific cases, especially when the disease involves multiple organs. For instance, mucopolysaccharidosis IIIB syndrome is a lysosomal storage disease with manifestations in many tissues, including hearing deficits, and is caused by loss of function mutations in the N-acetyl glucosaminidase gene NAGLU. 53 Recently, partial correction of hearing loss and other phenotypes were achieved by delivery of wild-type NAGLU using intravenous injection of recombinant lentivirus and intracranial injection of recombinant adeno-associated virus. 54 
PROSPECTS FOR THE FUTURE
The surgical approaches for gene transfer protocols need to be considered based on feasibility, risk, side effects and the actual outcome measured by the efficiency and specificity of gene expression. 55, 56 The delivery vectors and the routes of surgery need to be improved. For protecting the ears before an environmental lesion is inflicted, efficient gene transfer and small-molecule delivery procedures are needed, with a simplified method that does not involve side effects and can be done without a surgery.
Therapies that already showed initial success in animal models should be further developed for clinical applications. For treating hereditary deafness similar to that shown in the study by Akil et al., 1 it will be necessary to find a way to successfully rescue the function of the synapse in mature animal ears that will better model young (child) human ears. Extending the phenotypic rescue approach to other mutations, especially the most prevalent ones, will also be an important task.
For treating conditions with lost hair cells, it will be necessary to design an approach that will yield a sufficient number of hair cells that can survive, connect with the neural network and function. This will have to be accomplished days or weeks after the original hair cells are lost to better mimic the clinical reality. Similar goals face treatments aimed at improving the function of the stria vascularis to assist millions of aging ears with decreased function of the stria. Significant research efforts and resources are needed to accomplish these goals, but the combined contributions from laboratories around the globe raise hopes for breakthroughs and advances that will eventually pay off in the clinic.
